Bioxcel therapeutics reports positive overall survival results from single-arm, open-label phase 2 trial of bxcl701 in patients with metastatic castration-resistant prostate cancer (mcrpc) of adenocarcinoma phenotype

Median overall survival of 15.5 months with bxcl701 + keytruda® (pembrolizumab), compared to 9.6 months with checkpoint inhibitor monotherapy in late-line refractory patients in separate phase 2 trial 1

BTAI Ratings Summary

BTAI Quant Ranking